Ironwood Pharmaceuticals

$9.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-2.80%) Today
+$0.26 (+2.88%) As of 1:38 PM UTC after-hours

Why Robinhood?

You can buy or sell IRWD and other stocks, options, and ETFs commission-free!

About IRWD

Ironwood Pharmaceuticals, Inc. Class A Common Stock, also called Ironwood Pharmaceuticals, is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA. The listed name for IRWD is Ironwood Pharmaceuticals, Inc. Class A Common Stock.

CEO
Mark Mallon
Employees
232
Headquarters
Boston, Massachusetts
Founded
1998
Market Cap
1.48B
Price-Earnings Ratio
14.07
Dividend Yield
—
Average Volume
2.09M
High Today
$9.45
Low Today
$9.00
Open Price
$9.31
Volume
2.46M
52 Week High
$12.84
52 Week Low
$7.99

IRWD Earnings

-$0.03
$0.11
$0.26
$0.40
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.29 per share
Actual
$0.36 per share
Replay Earnings Call

You May Also Like

HBNC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure